In a milestone partnership, Knight-Dilan Research Hospital welcomed Dr. Elena Zhang’s Harvard team this week to jointly advance microfluidic breast-tumor models in their state-of-the-art Tumor-on-Chip Innovation Suite. Leading the collaboration, Senior Research Associate Sarah Montoya demonstrated how these chips faithfully recreate the breast-cancer microenvironment—fluid dynamics, oxygen gradients, and stromal cell interactions—all on a single glass slide.
Sarah guided the visitors past banks of illuminated incubators and the steady hum of perfusion systems to a row of translucent devices no larger than a smartphone. “Here, we grow living breast-cancer cells alongside supportive fibroblasts and a continuous trickle of nutrient medium,” she explained, pointing to a high-resolution camera feed. “ It truly behaves like a miniature tumor.”
Standing beside her, Professor Cyrus Jr. Knight added, “Traditional flat cultures can’t simulate the mechanical forces a tumor experiences in the body. Our platform lets us watch cancer cells respond in real time.” With a tap on the touchscreen, he initiated a controlled flow of chemotherapy drugs. Sensors immediately reported where cells underwent apoptosis and where escape pathways activated.
Dr. Zhang leaned forward, eyes bright. “On our own chips, we can’t replicate the spatial drug gradients you achieve here. It’s remarkable to observe resistance patterns emerge before our eyes.”
Over coffee in the hospital’s glass-walled atrium, the two teams sketched out next steps: integrating single-cell RNA sequencing to map transcriptional shifts, and testing patient-derived cells to personalize treatment screening. Plans are already underway to deploy simplified versions of these chips in Knight-Dilan’s mobile screening units, bringing point-of-care drug testing to rural clinics across Texas.
As the day closed, Sarah tucked her badge into her lab coat, reflecting on the partnership’s potential. “Tumor-on-chip isn’t just high-tech science—it’s a pathway to faster drug discovery and truly personalized oncology,” she said. At Knight-Dilan, where compassion drives innovation, Sarah Montoya and Professor Cyrus Jr. Knight are confident their work will set a new standard in cancer care—one microfluidic channel at a time.
Professor Knight, Sarah Montoya, Dr. Zhang and their teams gathered over coffee at Knight-Dilan’s atrium table, brainstorming next steps on tumor-on-chip and personalized oncology—all warmed by steaming mugs and bright ideas.
The Next Day in Dr. Sarah’s Lab
Dr. Sarah tapped the marker against the edge of the whiteboard, where a hand-drawn schematic of the new microfluidic assay kit sprawled across three panels. The lab’s afternoon light glinted off the rows of glass bottles and pipettes behind her. Around the high table, six students leaned in, their eyes fixed on the colorful diagram.
Dr. Sarah explaining the assay kit to her students
“Okay, everyone,” Sarah began, her tone both brisk and warm. “This kit is designed to recreate a patient’s tumor microenvironment on a chip. Let’s walk through it step by step.”
She circled the first panel: a small, clear cartridge etched with zig-zag channels. “Here’s the cell chamber. We seed it with your live sample—tumor cells mixed with stromal support cells—and let them settle into these grooves.” A student raised a hand. “How do we prevent the cells from clumping?” Sarah grinned. “Good question. That’s where the next module comes in.”
Moving to the middle panel, she pointed at a miniature peristaltic pump and tubing loops. “This perfusion system gently flows media through the chip. The rate—about five microliters per minute—keeps nutrients moving without shearing the cells. It also creates gradients of oxygen and drug we can tune in real time.”
A soft hum accompanied her flourish of the marker as she sketched tiny sensors along the channels. “Those gold-tone dots are built-in biosensors. They continuously measure pH and metabolic byproducts—so instead of waiting days for an endpoint assay, we get live feedback on how the cells respond to therapy.”
Sarah clicked her pen and the whiteboard switched to the final panel: a handheld reader with a touchscreen. “Once the run is complete, you slip the chip into this reader. It takes high-resolution images, analyzes sensor data, and spits out dose-response curves in minutes. That means we can test multiple drug combinations on a single sample—tailoring treatment faster than ever before.”
Hands shot up as students absorbed the promise of the system. “What about sterilization?” “How do we calibrate the sensors?” “Can we integrate immune cells, too?” With each question, Sarah guided them deeper: demonstrating how to prime the tubing with ethanol, walking them through calibration routines, and sketching out plans for co-culturing T-cells alongside tumor cells.
Dr. Sarah Montoya explains the tumor-on-chip platform to her students, pointing out the device’s microfluidic channels, stromal zones, and sensor arrays as a live breast-cancer model flows beneath their eyes. A whiteboard diagram and coffee cup complete the picture of innovation in action.
Dr. Sarah Montoya Explains Tumor-on-Chip
In the sleek, glass-walled lab, Dr. Sarah Montoya stood before a whiteboard dense with diagrams of microfluidic channels. Behind her, a row of transparent chips hummed gently under perfusion pumps. Students gathered around, notebooks ready.
“Here’s our prototype,” Sarah began, tracing a channel with her gloved finger. “Each microchannel mimics the structure of a breast tumor’s vasculature. We seed one channel with cancer cells, another with fibroblasts, then introduce fluid flow to recreate blood circulation.”
On the board she sketched drug gradients: red dye flowing from one inlet, blue from another, merging into a gradient. “When we add chemotherapy agents—like doxorubicin and paclitaxel—into these inlets,” she continued, “we can watch in real time how tumor cells die or mount resistance. That spatial drug gradient is impossible in 2D culture.”
she continued, sketching a rectangular chip with three parallel channels, “we’re going to build our own tumor-on-chip model—step by step.”
First, she drew the main cell chamber. “Here’s where we load our breast-cancer organoids. They’re suspended in a collagen–matrix hydrogel so they retain their 3D structure.” She labeled tiny inlet ports on one side. “These two inlets deliver fresh media and therapeutic drugs—mimicking the blood vessels feeding a real tumor.”
Next, she traced the narrow connecting channels. “Notice the 200-micron-wide microchannels. Fluid moves through at controlled rates—just like capillary flow in vivo—so we can create realistic shear stresses on the cells.”
She then added sensor icons along the top. “We’ve embedded pH and oxygen sensors here and here. That lets us monitor how cells respond—whether they consume oxygen faster under treatment or acidify their microenvironment.”
Pointing to a third compartment, she labeled it “stromal zone.” “This region holds fibroblasts or immune cells. Tumors don’t exist in isolation; their microenvironment can drive drug resistance or sensitivity. By coculturing these cell types, we capture those critical interactions.”
Dr. Sarah turned to face her students. “Once the chip is assembled, we mount it on our perfusion pump—this unit precisely controls flow rates between 1 to 10 microliters per minute. Then we run our experiment: record live-cell imaging, sample the outflow to measure secreted factors, and harvest cells afterward for single-cell RNA sequencing.”
She paused, letting her words sink in. “Tumor-on-chip systems bridge the gap between petri dishes and patients. They allow us to see, in real time, how a tumor evolves under mechanical forces, nutrient gradients, and targeted drugs—all on a device no larger than your smartphone.”
A hand shot up. “So we can test personalized therapies using a patient’s own cells?”
“Exactly,” Dr. Sarah smiled. “That’s the promise: rapid, patient-specific drug screening—and ultimately, smarter, faster routes to effective treatments.”
Another student raised her hand. “How do we measure cell response?”
Sarah smiled. “We integrate on-chip sensors—electrochemical probes that detect apoptotic markers—and then corroborate with live-cell imaging. We also collect effluent to run transcriptomic analysis, mapping changes at the single-cell level.”
She turned to the corner of the whiteboard where she’d listed databases and tools: PubMed for literature mining, GEO for expression data, TCGA for patient genomics. “These resources let us align our in-vitro findings with clinical datasets, guiding us to potential biomarkers for resistance.”
Another student asked about broader applications. “With patient-derived cells,” Sarah replied, “we can personalize screening—testing different drug combinations on each patient’s tumor chip before they ever receive treatment.”
As she wrapped up, Sarah tapped a final note: “Our goal is to deploy simplified chips in Knight-Dilan’s mobile units—screening patients in rural clinics, delivering precision oncology at the point of care.”
The students left energized, minds racing with possibilities. For them, tumor-on-chip wasn’t just another lab technique—it was the future of cancer research, bridging the gap between bench and bedside.
By the time she tapped the board to signal the end of her demo, the students were already clustering around the lab bench, prodding at the gleaming kit components. Dr. Sarah stepped back, satisfied. This wasn’t just theory—they could almost taste the future of precision oncology, one microfluidic channel at a time.
Dr. Sarah is illustrating the heart of our tumor-on-chip work at Knight-Dilan.